Thiazolidinediones: From antioxidant to neurotherapeutic?

Medical Hypotheses

Volumn 69, Issue 4, 2007, Pages 773-777

  McIntyre, Roger S ^a,b,c   Soczynska, Joanna K ^b,c   Woldeyohannes, Hanna ^c   Miranda, Andrew ^c   Konarski, Jakub Z ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDEPRESSANT AGENT; CORTICOSTERONE; GLIBENCLAMIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADD ON THERAPY; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEPRESSION; DRUG DOSE INCREASE; HUMAN; IMMUNITY; INFLAMMATION; MENTAL DISEASE; METABOLISM; MOOD DISORDER; MULTIPLE SCLEROSIS; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STRESS;

ANTIOXIDANTS; COGNITION DISORDERS; DEPRESSION; HUMANS; INFLAMMATION; METABOLISM; MODELS, BIOLOGICAL; MODELS, PSYCHOLOGICAL; NERVOUS SYSTEM DISEASES; STRESS; THIAZOLIDINEDIONES;

EID: 34547840262     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.078     Document Type: Article

References (30)

1. McEwen B.S. Mood disorders and allostatic load. Biol Psychiat 54 3 (2003) 200-207
2. Mathew S.J., Keegan K., and Smith L. Glutamate modulators as novel interventions for mood disorders. Rev Bras Psiquiatr 27 3 (2005) 243-248
3. Sheline Y.I., Wang P.W., Gado M.H., et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93 9 (1996) 3908-3913
4. MacQueen G.M., Campbell S., McEwen B.S., et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100 3 (2003) 1387-1392
5. Sheline Y.I., Sanghavi M., Mintun M.A., et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 19 12 (1999) 5034-5043
6. Drevets W.C. Neuroimaging studies of mood disorders. Biol Psychiat 48 8 (2000) 813-829
7. Konarski JZ, McIntyre RS, Grupp LA, Kennedy SH. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders. J Psychiat Neurosci, in press.
8. Kessing L.V. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 28 5 (1998) 1027-1038
9. Luna-Medina R., Cortes-Canteli M., Alonso M., et al. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 280 22 (2005) 21453-21462
10. Natarajan C., and Bright J.J. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 3 2 (2002) 59-70
11. Heneka M.T., Klockgether T., and Feinstein D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20 18 (2000) 6862-6867
12. Dello R.C., Gavrilyuk V., Weinberg G., et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278 8 (2003) 5828-5836
13. Fujita T., Sugiyama Y., Taketomi S., et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32 9 (1983) 804-810
14. Feinstein D.L. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5 1 (2003) 67-73
15. Feinstein D. Contrasting the neuroprotective and gliotoxic effects of PPARã agonistis. Drug Discov Today: Therapeut Strategies 1 1 (2004) 29-34
16. Musselman D.L., Betan E., Larsen H., et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiat 54 3 (2003) 317-329
17. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11 2 (2001) 240-249
18. Schiepers O.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog Neuropsychoph Biol Psychiat 29 2 (2005) 201-217
19. Capuron L., and Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiat 56 11 (2004) 819-824
20. Raison C.L., Capuron L., and Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27 1 (2006) 24-31
21. Khanzode S.D., Dakhale G.N., Khanzode S.S., et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8 6 (2003) 365-370
22. Collino M., Aragno M., Mastrocola R., et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530 1-2 (2006) 70-80
23. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 11 (2004) 1106-1118
24. Gelinas D.S., Lambermon M.H., and McLaurin J. Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. Brain Res 1034 1-2 (2005) 139-146
25. Landreth G.E., and Heneka M.T. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22 6 (2001) 937-944
26. Ialenti A., Grassia G., Di Meglio P., et al. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol Pharmacol 67 5 (2005) 1620-1628
27. Mayer J.L., Klumpers L., Maslam S., et al. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. J Neuroendocrinol 18 8 (2006) 629-631
28. Ialenti A., Grassia G., Di Meglio P., et al. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol Pharmacol 67 5 (2005) 1620-1628
29. Evans D.L., and Charney D.S. Mood disorders and medical illness: a major public health problem. Biol Psychiat 54 3 (2003) 177-180
30. Osby U., Brandt L., Correia N., et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiat 58 9 (2001) 844-850